For CBIO, its debt to operating expenses ratio is greater than that reported by only 5.81% of US equities we're observing.
Equity multiplier, or assets relative to shareholders' equity, comes in at 1.19 for Catalyst Biosciences Inc; that's greater than it is for just 11.35% of US stocks.
Catalyst Biosciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -47.97%, greater than the shareholder yield of just 8.66% of stocks in our set.
Stocks that are quantitatively similar to CBIO, based on their financial statements, market capitalization, and price volatility, are ETTX, ACIU, CDTX, SYBX, and LOGC.
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on engineering proteases as therapeutics for hemophilia, hemeostasis, complement-mediated diseases, and other unmet medical needs. The company is based in South San Francisco, California.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
The stock option was granted as an inducement material to Mr. Musil’s entering into employment with Catalyst in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option was granted outside of Catalyst’s 2018 Omnibus Incentive Plan, but except as set forth in the stock option agreement, will generally be subject to the same terms and conditions as apply to stock options granted under the plan.